The CFL2 antibody targets cofilin-2. a member of the cofilin family of actin-binding proteins critical for regulating cytoskeletal dynamics. Cofilin-2 (CFL2) is specifically expressed in striated muscle tissues, where it modulates actin filament turnover by severing and depolymerizing F-actin, enabling structural reorganization during muscle contraction and maintenance. Unlike its ubiquitously expressed isoform cofilin-1 (CFL1), CFL2's muscle-specific function highlights its role in sarcomere integrity and energy metabolism. Dysregulation of CFL2 is linked to myopathies, cardiomyopathies, and neuromuscular disorders, with mutations in the CFL2 gene associated with autosomal recessive nemaline myopathy and early-onset muscle weakness.
CFL2 antibodies are essential tools in biomedical research, facilitating the detection of cofilin-2 expression and localization via techniques like Western blotting, immunofluorescence, and immunohistochemistry. These antibodies help elucidate CFL2's involvement in muscle development, disease mechanisms, and potential therapeutic targets. Commercial CFL2 antibodies are typically raised in rabbits or mice, with specificity validated against recombinant proteins or tissue lysates. Recent studies also explore CFL2's phosphorylation status, as post-translational modifications influence its actin-binding activity and cellular localization. Understanding CFL2's role in health and disease continues to advance through antibody-based research, offering insights into muscle pathophysiology and strategies for treating related disorders.